Last reviewed · How we verify
Hydroxychloroquine combined with Azithromycin
Hydroxychloroquine inhibits endosomal acidification and toll-like receptor signaling while azithromycin provides macrolide antibiotic activity and immunomodulatory effects, together intended to reduce viral replication and inflammatory response.
Hydroxychloroquine inhibits endosomal acidification and toll-like receptor signaling while azithromycin provides macrolide antibiotic activity and immunomodulatory effects, together intended to reduce viral replication and inflammatory response. Used for COVID-19 (investigational, Phase 3).
At a glance
| Generic name | Hydroxychloroquine combined with Azithromycin |
|---|---|
| Sponsor | Ministry of Health, Turkey |
| Drug class | Antimalarial + Macrolide antibiotic combination |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
Hydroxychloroquine is an antimalarial agent that accumulates in lysosomes and endosomes, inhibiting their acidification and interfering with viral entry and replication pathways. Azithromycin is a macrolide antibiotic with immunomodulatory properties that can reduce pro-inflammatory cytokine production. The combination was investigated for synergistic antiviral and anti-inflammatory effects, particularly in viral respiratory infections.
Approved indications
- COVID-19 (investigational, Phase 3)
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- QT prolongation
- Retinopathy (hydroxychloroquine)
- Headache
Key clinical trials
- Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants (PHASE2)
- Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Randomised Evaluation of COVID-19 Therapy (PHASE3)
- Non-comparative Trial of the Combination of HCQ and AZI in the Treatment of ICU Patients (PHASE2)
- Hydroxychloroquine in Combination With Sirolimus and Dexamethasone for Treating COVID-19 Patients (NA)
- Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 (NA)
- Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: